Greenwich LifeSciences(NASDAQ) GLSI

Greenwich LifeSciences makes treatments to stop breast cancer from returning. These medicines help the immune system find and kill cancer cells. The company is testing its main drug in large global studies.

Fighting Cancer with Immunity

• GLSI-100: An immunotherapy treatment that combines a protein fragment called GP2 with an immune-system booster.
• GP2 Peptide: A specific protein target found in many common cancers, including 75% of all breast cancers.
• Flamingo-01: A Phase III clinical trial designed to test if the company's treatment prevents cancer recurrence in high-risk patients.

Moving onto the Global Stage

• Expanded the Flamingo-01 clinical trial into Europe with plans to open up to 150 sites globally for patient enrollment.
• Maintains an exclusive worldwide license for GP2 technology through an agreement with the Henry M. Jackson Foundation.
• Changed the corporate name to Greenwich LifeSciences in March 2018 to reflect its focus on biopharmaceutical development.

What Makes the Company Different

The company focuses on a specific group of breast cancer survivors who have finished standard treatments but still face a high risk of the disease returning. Its approach uses a targeted protein fragment to train the body's own immune cells to recognize and destroy remaining cancer cells.

The Cost of Development

• Annual net loss reached $19.4 million in 2025, which deepened from a $17.4 million loss in 2024.
• Accumulated deficit grew to $87.1 million as of December 31, 2025, reflecting heavy spending on clinical research.
• The company reported its first small revenue of $3,558 in the fourth quarter of 2025, up from zero the previous year.
• Operating cash flow remained negative at $2.7 million for the third quarter of 2025.

Bottom Line

Greenwich LifeSciences is a clinical-stage firm evolving into a global research organization focused on preventing cancer recurrence. Its future depends on the successful results and regulatory approval of its single lead immunotherapy candidate.